Strongest evidence
Substantial average weight reduction
SURMOUNT-1 reported roughly 15.0% to 20.9% average loss at 72 weeks across assigned groups.
COA VerifiedWeight Loss Peptides
Buy Tirzepatide in Canada: 20mg and 40mg Research Vials
5.03 reviews
● In stock — ships next business day$160.00
Purchase option
Strength
Buy more, save more
2+ vialsSave 5%
5+ vialsSave 10%
10+ vialsSave 15%
Not in stock yet. Leave your email and we will tell you when it is available.
Get notified when it's availableIndependently lab tested — 99%+ purity
COA number printed on every vial
Ships next business day, 1–3 day delivery
Discreet packaging · Interac e-Transfer
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in glucose-metabolism, appetite-regulation, and body-composition research. Each vial is lyophilized and independently tested. For research purposes only.
Store lyophilized vials refrigerated and protected from light and moisture. Follow the product-specific storage record after reconstitution.
Orders ship from within Canada in discreet packaging. Express delivery is typically 1–3 business days after dispatch.
Standard returns are not accepted because research materials cannot be safely restocked after delivery. Contact support promptly about damaged, incorrect, or compromised items.
Reconstitution calculator
Turn the vial amount into an easy-to-read volume
Enter three known values. The calculator converts the total vial amount and water added into a concentration, then shows the liquid volume and equivalent U-100 syringe units for the quantity entered.
The calculator does not choose a quantity. It converts the quantity you enter. One milligram equals 1,000 micrograms.
Bacteriostatic water is generally the most appropriate choice for multi-use research preparation because it contains a preservative for repeated vial access.
Concentration10 mg/mL1 mg in each 0.1 mL
Calculated liquid volume0.1 mL10 units on a U-100 syringe
Example using the values above: 20mg with 2mL of water equals 10mg/mL. A 1mg quantity equals 0.1mL, or 10 U-100 units.
Tirzepatide buyer and evidence guide
Understanding Tirzepatide: Weight-Loss Evidence, Expectations and Vial Choice
Tirzepatide is usually compared by weight-loss buyers who want more than a single GLP-1 pathway. It activates both GIP and GLP-1 receptors, with large human trials reporting substantial average weight reduction, reduced appetite, and improvements in several cardiometabolic measurements.
For a buyer, the important questions are how those results compare with Semaglutide, what digestive tradeoffs to expect, and whether the 20mg or 40mg vial is the more practical purchase. The two sizes list the same compound; the 40mg vial simply contains twice the total material.
Mechanism
Dual GIP and GLP-1
The two-receptor profile distinguishes Tirzepatide from Semaglutide's GLP-1-only approach.
Common tradeoff
Digestive tolerability
Nausea, diarrhea, constipation, vomiting, and reduced appetite are frequent issues.
Product decision
20mg vs 40mg
The 20mg vial lowers upfront cost; 40mg suits buyers who already need more total material.
Product specifications
- Research name
- Tirzepatide
- Compound class
- Dual incretin receptor agonist
- Research targets
- GIP and GLP-1 receptors
- Available strength
- 20mg and 40mg
- Form
- Lyophilized powder in a vial
- Listed purity
- 99%+
- Documentation
- The listing identifies independent testing and COA availability
- Dispatch country
- Canada
- Intended use
- Laboratory and in-vitro research only
Tirzepatide clinical evidence at a glance
The strongest buyer-relevant evidence comes from large trials of Lilly's authorized or investigational formulations.
| Evidence | Population and duration | What was reported | Buyer takeaway |
|---|---|---|---|
| SURMOUNT-1 Phase 3 | 2,539 adults without diabetes, 72 weeks | 15.0% to 20.9% average weight reduction across assigned groups | Strong human evidence; results vary by person |
| SURMOUNT-2 Phase 3 | Adults with obesity and type 2 diabetes, 72 weeks | Meaningful weight and A1C reductions | Diabetes status affects expected averages |
| SURMOUNT-4 maintenance trial | Adults after an initial Tirzepatide period | Continued treatment maintained and extended weight loss; withdrawal led to regain | Weight management behaves like a long-term process |
These outcomes came from standardized clinical formulations and cannot establish the performance, sterility, or fill accuracy of a separately sourced vial.
What is Tirzepatide and why do weight-loss buyers compare it?
Tirzepatide is a long-acting peptide with activity at GIP and GLP-1 receptors. Buyers usually compare it with Semaglutide because both have mature human evidence, while Tirzepatide reported larger average weight reductions in separate obesity trials.
Its appeal is not simply that two receptors must be better than one. The practical value comes from the clinical outcomes: appetite reduction, meaningful long-term weight change, glucose-related benefits, and improvements in several cardiometabolic markers in the populations studied.
Potential weight-loss benefits and realistic expectations
In SURMOUNT-1, adults with obesity or overweight without diabetes lost an average of 15.0%, 19.5%, or 20.9% of body weight at 72 weeks across the 5mg, 10mg, and 15mg assigned groups, compared with 3.1% with placebo. Participants received an authorized-quality investigational formulation, lifestyle support, stepwise increases, and clinical monitoring.
Those averages provide a useful benchmark, not a promise. Results continued over many months, some participants lost less, and others stopped because of adverse effects. People with type 2 diabetes often show a different average weight response than those without diabetes.
Tirzepatide compared with Semaglutide and Retatrutide
The primary distinction is the receptor combination each molecule is designed to engage.
| Compound | Primary targets | Research profile | Bison strengths |
|---|---|---|---|
| Semaglutide | GLP-1 | Single receptor | 10mg, 20mg |
| Tirzepatide | GIP and GLP-1 | Dual receptor | 20mg, 40mg |
| Retatrutide | GIP, GLP-1, and glucagon | Triple receptor | 10mg, 20mg |
Tirzepatide has authorized formulations and mature obesity evidence. Semaglutide has a longer GLP-1 evidence history, while Retatrutide remains investigational. Separate trial percentages are not direct head-to-head results.
Common side effects and practical expectations
The most common effects in Tirzepatide trials were gastrointestinal, including nausea, diarrhea, constipation, vomiting, abdominal symptoms, and reduced appetite. They occurred most often while exposure was increasing, which is why clinical protocols used gradual escalation.
Persistent vomiting or diarrhea can cause dehydration. Severe abdominal pain, allergic symptoms, fainting, confusion, or symptoms of very low blood glucose warrant prompt medical assessment. Insulin and sulfonylurea use, pregnancy, pancreatitis or gallbladder history, severe gastrointestinal disease, and certain thyroid-cancer histories require individualized medical screening.
20mg vs 40mg Tirzepatide: which vial fits the purchase?
The 20mg and 40mg labels describe total Tirzepatide in the vial. Both list the same compound. A 40mg vial contains twice the total material, but it is not automatically a stronger individual amount, a higher level, or a faster option.
For a first purchase, 20mg is usually the more practical choice because the upfront cost and potential unused material are lower. Choose 40mg when you already know you need twice the total quantity and the larger vial offers better displayed value per milligram.
How to evaluate Tirzepatide quality before buying
The listing identifies independent testing and COA availability. Before ordering, confirm that the available certificate identifies the compound or blend, batch or lot, test date, analytical method, and reported result. After delivery, compare the vial label with that exact documentation rather than relying on a generic certificate.
Identity, purity, fill quantity, sterility, and endotoxin testing answer different questions. A large purity percentage does not prove every other quality attribute, so buyers should check which tests are actually reported and avoid assuming that an unlisted result was performed.
Research-use and approval status
The Bison Peptides Tirzepatide vial is supplied as a technical laboratory research material, not an authorized prescription formulation. The page summarizes published research to help buyers understand the compound, evidence, and product format; it is not an individual treatment or dosing recommendation.
Related research pages
Primary sources and status references
- PubMed: Tirzepatide dual-receptor signaling profile
- PubMed: SURMOUNT-1 Tirzepatide obesity trial
- PubMed: SURMOUNT-4 Tirzepatide maintenance trial
- FDA: Current Zepbound prescribing information
- Health Canada: Warning about unauthorized peptide products
Content reviewed August 11, 2026 by the Bison Peptides editorial team.
Reviews
5.03 reviews
Happy with the 40mg option
“I specifically wanted the larger 40mg size and was glad to find it available. The ordering process was easy and the vial arrived safely with clear labeling. Everything looked exactly like it did online. Very good first impression of the company.”
40mg ·
Amanda P. · Verified buyer
Great first order
“Ordered the 20mg Tirzepatide for my first purchase. Checkout was simple and the package arrived in excellent condition. The vial was well protected inside the shipment and the branding looks great in person. Overall a very smooth experience.”
20mg ·
Trevor W. · Verified buyer
Consistent quality and packaging
“This was my second purchase and I went with the 40mg strength again. Both orders have arrived well packaged and everything has been consistent between them. Clear labels, good communication, and no surprises when the package arrives. That's really what I look for when ordering online.”
40mg ·
Samantha G. · Verified buyer
Frequently asked questions
What benefits is Tirzepatide studied for?
Tirzepatide has extensive human research for appetite reduction, body-weight management, A1C and glucose control, and cardiometabolic measurements. In SURMOUNT-1, average weight reduction ranged from 15.0% to 20.9% across assigned groups at 72 weeks.
How quickly did people lose weight with Tirzepatide in trials?
Weight changed progressively over many months. SURMOUNT-1 measured the main outcome at 72 weeks, and a later analysis found that some slower responders still reached meaningful reductions after the first few months.
What is the difference between 20mg and 40mg Tirzepatide?
The difference is total material in the vial. The listed compound is the same. A 40mg vial contains twice as much total Tirzepatide, not a different or automatically stronger version.
Which Tirzepatide vial is better for a first order?
The 20mg vial is usually the more practical first purchase because it costs less up front and limits potential unused material. Choose 40mg when you already expect to need the larger total quantity and want the better displayed value per milligram.
Is Tirzepatide better than Semaglutide for weight loss?
Tirzepatide reported larger average reductions in its own obesity trial, but the studies were not a single head-to-head comparison and used different designs. Semaglutide has a longer evidence history, while Tirzepatide's dual-receptor profile and trial averages are why many buyers compare it.
How does Tirzepatide compare with Retatrutide?
Tirzepatide targets GIP and GLP-1 and has authorized prescription formulations. Retatrutide adds glucagon-receptor activity but remains investigational. Retatrutide's early results are promising, but Tirzepatide currently has the more mature approval and safety evidence.
What are common Tirzepatide side effects?
Nausea, diarrhea, constipation, vomiting, abdominal symptoms, and reduced appetite are the most common. Severe or persistent symptoms require medical assessment, particularly when dehydration, abdominal pain, allergic symptoms, or low blood glucose may be involved.
Is this product the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are authorized prescription medicines with specific formulations, devices, manufacturing controls, and indications. A lyophilized research vial is not interchangeable with those products.
